Jonathan Metts, MD

Cancer Focus:
Osteosarcoma, Sarcoma

Dr. Metts specializes in the care of adolescents and young adults with sarcoma. He received his MD degree from the University of South Carolina School of Medicine. He completed a Pediatric Residency at the University South Florida Morsani School of Medicine followed by a Pediatric Hematology/Oncology Fellowship at Emory University School of Medicine and the Aflac Cancer and Blood Disorders Center at Children's Healthcare of Atlanta. Dr. Metts joins us from Johns Hopkins All Children’s Hospital in St. Petersburg, Florida where he continues clinical care and research as a part-time Assistant Professor in the Cancer and Blood Disorders Institute. Dr. Metts research interests include novel therapies and clinical trials for patients with sarcomas and other tumors as well as cellular therapy for pediatric solid tumors, including tumor infiltrating lymphocyte therapy. Dr. Metts is Co-Chairman of the National Pediatric Cancer Foundation's Sunshine Project, a clinical trials and translational research consortium comprised of leading pediatric oncology institutions across the United States with a mission to identify more effective and less toxic treatments for children with cancer.    

Clinical Trial 20339
Evolutionary Inspired Therapy for Newly Diagnosed, Metastatic, Fusion Positive Rhabdomyosarcoma
Condition: Sarcoma
Intervention: Actinomycin D (Dactinomycin); Adriamycin (doxorubicin); Ifosfamide (); Navelbine (Vinorelbine); Radiotherapy (); Vincristine (); Vinorelbine (); cyclophosphamide (); cytoxan (cyclophosphamide); doxorubicin (); etoposide ()
Status: Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

• Farrar A, Blanco P, Fabbrini A, Armstrong L, Metts J, Monforte H, Karjoo S, Danielson P, Wilsey M. Appendiceal mucinous neoplasm in adolescence: Diagnosis, management, and surveillance. JPGN Rep. 2024 Feb.5(1):66-69. Pubmedid: 38545266. Pmcid: PMC10964329.
• Metts J, Xue W, Gao Z, Oberoi S, Weiss AR, Venkatramani R, Harrison DJ. Event-free survival in relapsed and refractory rhabdomyosarcoma treated on cooperative group phase II trials: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2024 Apr.e31009. Pubmedid: 38627882.
• Cho S, Miller A, Mosha M, McNerney KO, Metts J. Clinical Trials on Cellular Therapy for Children and Adolescents With Cancer: A 15-Year Trend in the United States. Cureus. 2023 Oct.15(10):e47885. Pubmedid: 38021600. Pmcid: PMC10681796.
• Welch DL, Fridley BL, Cen L, Teer JK, Yoder SJ, Pettersson F, Xu L, Cheng CH, Zhang Y, Alexandrow MG, Xiang S, Robertson-Tessi M, Brown JS, Metts J, Brohl AS, Reed DR. Modeling phenotypic heterogeneity towards evolutionarily inspired osteosarcoma therapy. Sci Rep. 2023 Nov.13(1):20125. Pubmedid: 37978271. Pmcid: PMC10656496.
• Metts J, Xue W, Gao Z, Ermoian R, Bradley JA, Arnold MA, Dasgupta R, Venkatramani R, Walterhouse D. Survival of patients with orbital and eyelid rhabdomyosarcoma treated on Children's Oncology Group studies from 1997 to 2013: A report from the Children's Oncology Group. Cancer. 2023 Jun.129(11):1735-1743. Pubmedid: 36857314. Pmcid: PMC10288338.
• Shaw PH, Metts J, Amankwah E, Eslin DE, Bradfield S, Slayton WB, Hays B, Calkins B, Rico J, Krischer J. Trends in Pediatric Cancer Care in Florida From 1981-2020: Changing Patterns in a Growing and Increasingly Diverse Population. Cureus. 2023 Feb.15(2):e35061. Pubmedid: 36938203. Pmcid: PMC10023130.
• Metts JL, Trucco M, Weiser DA, Thompson P, Sandler E, Smith T, Crimella J, Sansil S, Thapa R, Fridley BL, Llosa N, Badgett T, Gorlick R, Reed D, Gill J. A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation. Cancer Med. 2023 Feb.12(4):4270-4281. Pubmedid: 36151773. Pmcid: PMC9972017.
• Morris D, Gonzalez R, Cook J, Metts J, Shaw P. Gastrointestinal Complications of Intra-Abdominal Desmoid Tumors: A Case Report and Review of the Literature. Case Rep Oncol. 2022 May.15(2):515-521. Pubmedid: 35813700. Pmcid: PMC9209997.
• Metts J, Harrington B, Salman E, Bradfield SM, Flanary J, Mosha M, Amankwah E, Stapleton S. A phase I study of irinotecan and temozolomide with bevacizumab in children with recurrent/refractory central nervous system tumors. Childs Nerv Syst. 2022 May.38(5):919-928. Pubmedid: 35260913.
• Hensel J, Metts J, Gupta A, Ladle BH, Pilon-Thomas S, Mullinax J. Adoptive Cellular Therapy for Pediatric Solid Tumors: Beyond Chimeric Antigen Receptor-T Cell Therapy. Cancer J. 2022 Jul.28(4):322-327. Pubmedid: 35880942. Pmcid: PMC9847472.
• Metts J, Russell T, Reed D, Trucco M. A Proposed Trial Design for the Treatment of Widely Metastatic Ewing Sarcoma Inspired by Evolutionary Dynamics. Cancers (Basel). 2022 Jan.14(3). Pubmedid: 35159003. Pmcid: PMC8833360.
• Gaefke CL, Metts J, Imanirad D, Nieves D, Terranova P, Dell'Orso G, Gambineri E, Miano M, Lockey RF, Walter JE, Westermann-Clark E. Case Report: A Novel Pathogenic Missense Mutation in FAS: A Multi-Generational Case Series of Autoimmune Lymphoproliferative Syndrome. Front Pediatr. 2021 Mar.9:624116. Pubmedid: 33816397. Pmcid: PMC8012668.
• Wang Z, Mi T, Bradley HL, Metts J, Sabnis H, Zhu W, Arbiser J, Bunting KD. Pimozide and Imipramine Blue Exploit Mitochondrial Vulnerabilities and Reactive Oxygen Species to Cooperatively Target High Risk Acute Myeloid Leukemia. Antioxidants (Basel). 2021 Jun.10(6). Pubmedid: 34203664. Pmcid: PMC8232307.
• Westermann-Clark E, Meehan CA, Meyer AK, Dasso JF, Amre D, Ellison M, Patel B, Betensky M, Hauk CI, Mayer J, Metts J, Leiding JW, Sriaroon P, Kumar A, Ayala I, Walter JE. Primary Immunodeficiency in Children With Autoimmune Cytopenias: Retrospective 154-Patient Cohort. Front Immunol. 2021 Apr.12:649182. Pubmedid: 33968040. Pmcid: PMC8100326.
• Sabnis HS, Minson KA, Monroe C, Allen K, Metts JL, Cooper TM, Woods WG, Castellino SM, Keller FG. A strategy to reduce cumulative anthracycline exposure in low-risk pediatric acute myeloid leukemia while maintaining favorable outcomes. Leuk Res. 2020 Sep.96:106421. Pubmedid: 32683126.
• Reed DR, Metts J, Pressley M, Fridley BL, Hayashi M, Isakoff MS, Loeb DM, Makanji R, Roberts RD, Trucco M, Wagner LM, Alexandrow MG, Gatenby RA, Brown JS. An evolutionary framework for treating pediatric sarcomas. Cancer. 2020 Jun.126(11):2577-2587. Pubmedid: 32176331. Pmcid: PMC7318114.
• Metts JL, Park SI, Briones MA, Keller FG. Hemophagocytic Lymphohistiocytosis Secondary to T Cell/Histiocyte-rich Large B Cell Lymphoma in an Adolescent Male. Pediatr Dev Pathol. 2019 May.21(1):95-99. Pubmedid: 29187030.
• Metts JL, Alazraki AL, Clark D, Amankwah EK, Wasilewski-Masker KJ, George BA, Olson TA, Cash T. Gemcitabine/nab-paclitaxel for pediatric relapsed/refractory sarcomas. Pediatr Blood Cancer. 2018 Sep.65(9):e27246. Pubmedid: 29770997.
• Metts JL, Park SI, Soares BP, Fong C, Biegel JA, Goldsmith KC. Concurrent myeloid sarcoma, atypical teratoid/rhabdoid tumor, and hypereosinophilia in an infant with a germline SMARCB1 mutation. Pediatr Blood Cancer. 2017 Sep.64(9). Pubmedid: 28111898.
• Metts J, Bradley HL, Wang Z, Shah NP, Kapur R, Arbiser JL, Bunting KD. Imipramine blue sensitively and selectively targets FLT3-ITD positive acute myeloid leukemia cells. Sci Rep. 2017 Jun.7(1):4447. Pubmedid: 28667329. Pmcid: PMC5493614.

Title: Feasibility of Generating Novel Translational and Therapeutic Strategies based on a Multicenter, Pediatric and AYA Evolutionary Tumor Board; pedsETB
Sponsor: Florida Biomedical Research Program (FBRP)
PI: Metts, J., CO-PI: Robertson-Tessi, M., CO-PI: Anderson, A., CO-PI: Brown, J., CO-PI: Marusyk, A.
Title: Evolutionary Inspired Therapy for Newly Diagnosed, Metastatic, Fusion Positive Rhabdomyosarcoma
Sponsor: Florida Biomedical Research Program (FBRP)
PI: Metts, J.